NEXIEN BIOPHARMA, INC. Contracts & Agreements
17 Contracts & Agreements
- Business Finance (12 contracts)
- Human Resources (3)
- Intellectual Property (2)
- Convertible Promissory Note dated February 14, 2024 issued to Quick Capital, LLC (Filed With SEC on February 20, 2024)
- Note Purchase Agreement dated February 14, 2024 between the Company and Quick Capital, LLC (Filed With SEC on February 20, 2024)
- Amendment and Extension of Note Purchase Agreement dated May 8, 2023 (Filed With SEC on September 28, 2023)
- Note Purchase Agreement dated January 18, 2022 between the Company and Quick Capital, LLC (Filed With SEC on January 21, 2022)
- Convertible Promissory Note dated January 18, 2022 issued to Quick Capital, LLC (Filed With SEC on January 21, 2022)
- Common Stock Purchase Warrant dated January 18, 2022 issued to Quick Capital, LLC (Filed With SEC on January 21, 2022)
- Convertible Promissory Note and Warrants dated November 24, 2020 to Richard Greenberg (Filed With SEC on February 11, 2021)
- Demand Convertible Promissory Note dated June 11, 2020 to Richard Greenberg (Filed With SEC on September 28, 2020)
- Limited Liability Company Interest Purchase Agreement by and among the Members of CRX Bio Holdings LLC and Nexien BioPharma, Inc. dated October 26, 2018 (Filed With SEC on October 30, 2018)
- Form of Class E Warrant (Filed With SEC on September 28, 2018)
- First Amendment to Exclusive License Agreement between the Company and Accu-Break Pharmaceuticals, Inc. dated September 18, 2018 (Filed With SEC on September 28, 2018)
- Form of Class D Warrant (Filed With SEC on September 28, 2018)
- 2017 Stock Incentive Plan (Filed With SEC on May 15, 2018)
- Licensing Agreement between the Company and Kotzker Consulting LLC (Filed With SEC on May 15, 2018)
- Exclusive License Agreement between the Company and Accu-Break Pharmaceuticals, Inc (Filed With SEC on May 15, 2018)
- 2018 Equity Incentive Plan (Filed With SEC on May 15, 2018)
- Amended and Restated Share Exchange Agreement between the Registrant and Intiva BioPharma Inc., dated October 13, 2017 (Filed With SEC on October 16, 2017)